Amedeo Smart

Free Medical Literature Service

 

Amedeo

Antiretroviral Therapy
  Free Subscription

Articles published in
Antimicrob Agents Chemother
    September 2025
  1. YAO B-F, Yang Y, Xu S-S, Tang B-H, et al
    Model-informed drug development in public health emergency of international concern: accelerating marketing authorization of simnotrelvir.
    Antimicrob Agents Chemother. 2025 Sep 18:e0061425. doi: 10.1128/aac.00614.
    >> Share

    July 2025
  2. VAN SCHALKWYK M, Bekker A, Decloedt E, Wang J, et al
    Pharmacokinetics of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum with and without efavirenz-based antiretroviral treatment: IMPAACT P1026s study.
    Antimicrob Agents Chemother. 2025 Jul 31:e0005225. doi: 10.1128/aac.00052.
    >> Share

    March 2025
  3. ZHAO L, Li C, Wang M, Zhou M, et al
    Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrier.
    Antimicrob Agents Chemother. 2025 Mar 10:e0155624. doi: 10.1128/aac.01556.
    >> Share

    February 2025
  4. HE M-W, Cui L, Chen D-D, Zhao Y, et al
    Efficacy and safety of switching from entecavir to tenofovir alafenamide in chronic hepatitis B patients with low-level viremia: a real-world 48-week extension study.
    Antimicrob Agents Chemother. 2025 Feb 4:e0182724. doi: 10.1128/aac.01827.
    >> Share

    January 2025
  5. HU Y, Li H, Wang K, Wu D, et al
    Single- and multiple-dose pharmacokinetics and safety of the SARS-CoV-2 3CL protease inhibitor RAY1216: a phase 1 study in healthy participants.
    Antimicrob Agents Chemother. 2025 Jan 31:e0145024. doi: 10.1128/aac.01450.
    >> Share

    December 2024
  6. NDZAMBA B, Denti P, McIlleron H, Smith P, et al
    Pharmacokinetics of ethambutol and weight banded dosing in South African adults newly diagnosed with tuberculosis and HIV.
    Antimicrob Agents Chemother. 2024 Dec 23:e0120024. doi: 10.1128/aac.01200.
    >> Share

    September 2024
  7. MARZINKE MA, Han K, Hanscom B, Guo X, et al
    Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084.
    Antimicrob Agents Chemother. 2024 Sep 23:e0099424. doi: 10.1128/aac.00994.
    >> Share

    August 2024
  8. TIAN P, Li Q-Q, Guo M-J, Zhu Y-Z, et al
    Zidovudine in synergistic combination with nitrofurantoin or omadacycline: in vitro and in murine urinary tract or lung infection evaluation against multidrug-resistant Klebsiella pneumoniae.
    Antimicrob Agents Chemother. 2024 Aug 28:e0034424. doi: 10.1128/aac.00344.
    >> Share

    July 2024
  9. BAE J, Tantawy M, Gong Y, Langaee T, et al
    Pharmacogenetic determinants of tenofovir diphosphate and lamivudine triphosphate concentrations in people with HIV/HBV coinfection.
    Antimicrob Agents Chemother. 2024 Jul 30:e0054924. doi: 10.1128/aac.00549.
    >> Share

  10. SEMERE GEBREYESUS M, Wasmann RE, McIlleron H, Oladokun R, et al
    Population pharmacokinetics of rifabutin among HIV/TB co-infected children on lopinavir/ritonavir-based antiretroviral therapy.
    Antimicrob Agents Chemother. 2024 Jul 22:e0035424. doi: 10.1128/aac.00354.
    >> Share

  11. ZHOU J, Zhang H, Chen H, Zhang G, et al
    Pharmacokinetics and safety of GST-HG171, a novel 3CL protease inhibitor, in Chinese subjects with impaired and normal liver function.
    Antimicrob Agents Chemother. 2024 Jul 11:e0053924. doi: 10.1128/aac.00539.
    >> Share

    May 2024
  12. PANJASAWATWONG N, Avihingsanon A, Menetrey C, Ribeiro I, et al
    Population pharmacokinetics of ravidasvir in adults with chronic hepatitis C virus infection and impact of antiretroviral treatment.
    Antimicrob Agents Chemother. 2024 May 20:e0000824. doi: 10.1128/aac.00008.
    >> Share

    April 2024
  13. CHANDASANA H, Singh R, Adkison K, Ait-Khaled M, et al
    Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1.
    Antimicrob Agents Chemother. 2024 Apr 8:e0150423. doi: 10.1128/aac.01504.
    >> Share

    March 2024
  14. WANG C, Yu X, Ke Y, Fu Y, et al
    Efficacy and effect on lipid profiles of switching to ainuovirine-based regimen versus continuing efavirenz-based regimen in people with HIV-1: 24-week results from a real-world, retrospective, multi-center cohort study.
    Antimicrob Agents Chemother. 2024 Mar 14:e0166823. doi: 10.1128/aac.01668.
    >> Share

    February 2024
  15. MULATO A, Lansdon E, Aoyama R, Voigt J, et al
    Preclinical characterization of a non-peptidomimetic HIV protease inhibitor with improved metabolic stability.
    Antimicrob Agents Chemother. 2024 Feb 21:e0137323. doi: 10.1128/aac.01373.
    >> Share

    January 2024
  16. YANG H, Yu X, Hou W, Liu X, et al
    Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19.
    Antimicrob Agents Chemother. 2024 Jan 30:e0138423. doi: 10.1128/aac.01384.
    >> Share

    December 2023
  17. ZHANG H, Zhou J, Chen H, Mao J, et al
    Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171.
    Antimicrob Agents Chemother. 2023 Dec 15:e0111523. doi: 10.1128/aac.01115.
    >> Share

  18. ABDALLA S, Compagnucci A, Riault Y, Chan MK, et al
    Simultaneous pharmacokinetic modeling of unbound and total darunavir with ritonavir in adolescents: a substudy of the SMILE trial.
    Antimicrob Agents Chemother. 2023 Dec 11:e0100423. doi: 10.1128/aac.01004.
    >> Share

    October 2023
  19. KENGO A, Gausi K, Nabisere R, Musaazi J, et al
    Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin.
    Antimicrob Agents Chemother. 2023 Oct 18:e0043123. doi: 10.1128/aac.00431.
    >> Share

    May 2023
  20. HAO X, Ni J, Zhao D, Zhang W, et al
    No Meaningful Drug-Drug Interactions Are Associated with the Coadministration of ACC007, Lamivudine, and Tenofovir Disoproxil Fumarate.
    Antimicrob Agents Chemother. 2023 May 1:e0121922. doi: 10.1128/aac.01219.
    >> Share

    April 2023
  21. BERTRAND J, Barrail-Tran A, Fayette L, Savic R, et al
    Pharmacokinetic Model of Tenofovir and Emtricitabine and Their Intracellular Metabolites in Patients in the ANRS 134-COPHAR 3 Trial Using Dose Records.
    Antimicrob Agents Chemother. 2023 Apr 26:e0233918. doi: 10.1128/aac.02339.
    >> Share

  22. ELGAMMAL Y, Salama EA, Seleem MN
    Atazanavir Resensitizes Candida auris to Azoles.
    Antimicrob Agents Chemother. 2023 Apr 24:e0163122. doi: 10.1128/aac.01631.
    >> Share

    March 2023
  23. MARZINKE MA, Fogel JM, Wang Z, Piwowar-Manning E, et al
    Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
    Antimicrob Agents Chemother. 2023 Mar 30:e0005323. doi: 10.1128/aac.00053.
    >> Share

  24. HONG H, Aslam-Mir U, Kajubi R, Wallender E, et al
    Efavirenz-Based Antiretroviral Therapy but Not Pregnancy Increased Unbound Piperaquine Exposure in Women during Malaria Chemoprevention.
    Antimicrob Agents Chemother. 2023 Mar 14:e0142722. doi: 10.1128/aac.01427.
    >> Share

    February 2023
  25. CHIREHWA MT, Resendiz-Galvan JE, Court R, De Kock M, et al
    Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling.
    Antimicrob Agents Chemother. 2023 Feb 6:e0142622. doi: 10.1128/aac.01426.
    >> Share

    December 2022
  26. BURDETTE D, Hyrina A, Song Z, Beran RK, et al
    Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection.
    Antimicrob Agents Chemother. 2022 Dec 15:e0134822. doi: 10.1128/aac.01348.
    >> Share

    November 2022
  27. BANDA CG, Nkosi D, Allen E, Workman L, et al
    Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV.
    Antimicrob Agents Chemother. 2022 Nov 14:e0058422. doi: 10.1128/aac.00584.
    >> Share

    October 2022
  28. LINGSCHEID T, Kinzig M, Kruger A, Muller N, et al
    Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis.
    Antimicrob Agents Chemother. 2022 Oct 26:e0122922. doi: 10.1128/aac.01229.
    >> Share

    August 2022
  29. PHAM MM, Podany AT, Mwelase N, Supparatpinyo K, et al
    Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.
    Antimicrob Agents Chemother. 2022 Aug 9:e0238521. doi: 10.1128/aac.02385.
    >> Share

    July 2022
  30. DEVANATHAN AS, White NR, Desyaterik Y, De la Cruz G, et al
    Quantitative Imaging Analysis of the Spatial Relationship between Antiretrovirals, Reverse Transcriptase Simian-Human Immunodeficiency Virus RNA, and Fibrosis in the Spleens of Nonhuman Primates.
    Antimicrob Agents Chemother. 2022 Jul 20:e0060922. doi: 10.1128/aac.00609.
    >> Share

  31. MTSHALI S, Jacobs BA
    A Comparative Analysis of Physiologically Based Pharmacokinetic Models for Human Immunodeficiency Virus and Tuberculosis Infections.
    Antimicrob Agents Chemother. 2022 Jul 19:e0027422. doi: 10.1128/aac.00274.
    >> Share

  32. KIM JH, Kim JH, Choe WH, Kwon SY, et al
    Switching from Tenofovir-Based Combination Therapy to Tenofovir Monotherapy in Multidrug-Experienced Chronic Hepatitis B Patients: a 5-Year Experience at Two Centers.
    Antimicrob Agents Chemother. 2022 Jul 13:e0027522. doi: 10.1128/aac.00275.
    >> Share

  33. ATMAR RL, Finch N
    New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.
    Antimicrob Agents Chemother. 2022 Jul 12:e0240421. doi: 10.1128/aac.02404.
    >> Share

    May 2022
  34. DE NICOLO A, Calcagno A, Motta I, De Vivo E, et al
    The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study.
    Antimicrob Agents Chemother. 2022 May 18:e0013622. doi: 10.1128/aac.00136.
    >> Share

  35. VAN DER LAAN LE, Garcia-Prats AJ, Schaaf HS, Chirehwa M, et al
    Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2022 May 4:e0226421. doi: 10.1128/aac.02264.
    >> Share

  36. LAI MT, Feng M, Xu M, Ngo W, et al
    Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.
    Antimicrob Agents Chemother. 2022 May 2:e0222321. doi: 10.1128/aac.02223.
    >> Share

    April 2022
  37. ACOSTA RK, D'Antoni ML, Mulato A, Yant SR, et al
    Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence In Vitro.
    Antimicrob Agents Chemother. 2022 Apr 7:e0203821. doi: 10.1128/aac.02038.
    >> Share

    March 2022
  38. MOORE K, Thakkar N, Magee M, Sevinsky H, et al
    Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
    Antimicrob Agents Chemother. 2022 Mar 22:e0225121. doi: 10.1128/aac.02251.
    >> Share

  39. WALLACE J, Gonzalez H, Rajan R, Narasipura SD, et al
    Anti-HIV Drugs Cause Mitochondrial Dysfunction in Monocyte-Derived Macrophages.
    Antimicrob Agents Chemother. 2022 Mar 16:e0194121. doi: 10.1128/aac.01941.
    >> Share

  40. MWANGI JN, Gilliland WM Jr, White N, Sykes C, et al
    Mass Spectroscopy Imaging of Hair Strands Captures Short-Term and Long-Term Changes in Emtricitabine Adherence.
    Antimicrob Agents Chemother. 2022 Mar 10:e0217621. doi: 10.1128/aac.02176.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016